Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07569822

Effect of Vibrator Use on Symptoms of Urgency Urinary Incontinence, Sexual Function, and Sleep

This study aims to understand if using a vibrator affects urgency related urinary incontinence. Insights from this study may open new recommendations for treating urinary urgency and incontinence.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

About this study

This is a randomized superiority trial designed to evaluate the efficacy of scheduled vibrator use as an adjunct to standard lifestyle and behavioral modifications for urgency urinary incontinence (UUI) or urgency-predominant mixed urinary incontinence (MUI). UUI is defined as involuntary urine leakage preceded by a sudden, compelling urge to void. This will be identified and confirmed by patient report and screening with urgency-related items on the Urogenital Distress Inventory-6 (UDI-6), with participants required to report urgency-related leakage at least once per week.

Eligible participants will be recruited from the Albany Medical Center Urogynecology clinic during routine outpatient visits. After informed consent and baseline assessment, participants will be randomized 1:1 to either (1) lifestyle and bladder training counseling alone (control arm) or (2) lifestyle and bladder training counseling plus scheduled vibrator use (intervention arm). Participants in the intervention group will be instructed to use a provided FDA-registered Class II wellness vibrator for 5-10 minutes at least three times per week over an eight-week period, while all participants will receive standardized bladder retraining education materials. The primary outcome measure will be change in UDI-6 score, Female Sexual Function Index (FSFI), and Brief Pittsburgh Sleep Quality Index (B-PSQI) from baseline to eight weeks. Secondary outcomes will include validated assessments of quality of life and distress, including the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12), Patient Global Impression of Improvement (PGI-I), Patient Health Questionnaire-4 (PHQ-4).

The study will be conducted at Albany Medical Center, Department of Obstetrics and Gynecology, Division of Urogynecology and Pelvic Reconstructive Surgery, following approval by the Institutional Review Board (IRB).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Assigned female at birth.
  • Age ≥18 years.
  • Able to read and speak English.
  • Diagnosis of urgency urinary incontinence or mixed urinary incontinence (based on clinical assessment and UDI-6 urgency questions).
  • Leaks urine at least once per week due to urgency.
  • Postvoid residual volume <100 mL or a third of the voided volume

Exclusion criteria

  • Pelvic organ prolapse beyond the hymen
  • Neurogenic bladder, multiple sclerosis, or other neurologic causes of incontinence.
  • Recurrent urinary tract infection (>3 UTIs in the past year or >2 in the past 6 months).
  • Active urinary tract infection at the time of enrollment.
  • Interstitial cystitis/bladder pain syndrome.
  • Current use of sacral neuromodulation or percutaneous tibial nerve stimulation (PTNS).
  • Bladder Botox injection within the past 6 months.
  • Vibrator use within the past 3 months.
  • Patients uncomfortable with vibrator use
  • Pregnancy or plans for pregnancy during the study period.

Treatment and study plan

Vibrator

Device

Scheduled vibrator use

Behavioral modification

Behavioral

Guideline based standard lifestyle and behavioral modifications for urgency urinary incontinence

Primary outcomes

  1. Change in score on UDI-6 from baseline to follow-up in 8 weeks.

    Time frame: 12 weeks

    Submitted

Secondary outcomes

  1. Female Sexual Function Index (FSFI)

    Time frame: 12 weeks

    The Female Sexual Function Index is a 19-item questionnaire assessing domains of sexual function including desire, arousal, lubrication, orgasm, satisfaction, and pain. Scores range from 2 to 36, with higher scores indicating better sexual function and lower likelihood of dysfunction.

  2. Brief Pittsburgh Sleep Quality Index (B-PSQI)

    Time frame: 12 weeks

    The Brief Pittsburgh Sleep Quality Index is a shortened version of the Pittsburgh Sleep Quality Index that evaluates sleep quality and disturbances over a recent time period. Scores typically range from 0 to 15 (depending on version), with higher scores indicating worse sleep quality.

  3. Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR)

    Time frame: 12 weeks

    The PISQ-IR assesses sexual function in women with pelvic floor disorders and includes separate scoring for sexually active and non-sexually active individuals. Scores vary by domain, but are generally transformed to a 0-100 scale, with higher scores indicating better sexual function and condition-specific quality of life.

  4. Patient Global Impression of Improvement (PGI-I)

    Time frame: 12 weeks

    The Patient Global Impression of Improvement is a single-item scale that asks patients to rate their condition after treatment compared to baseline. It ranges from 1 (very much better) to 7 (very much worse), with lower scores indicating better outcomes/improvement.

  5. Patient Health Questionnaire-4 (PHQ-4)

    Time frame: 12 weeks

    The Patient Health Questionnaire-4 is an ultra-brief screening tool combining 2 items for anxiety and 2 for depression. Scores range from 0 to 12, with higher scores indicating greater psychological distress.

  6. International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)

    Time frame: 12 weeks

    The International Consultation on Incontinence Questionnaire-Short Form evaluates the frequency, severity, and impact of urinary incontinence on quality of life. Scores range from 0 to 21, with higher scores indicating more severe symptoms and worse quality of life impact.

Study contacts

Contact information is provided by the study sponsor or research team.

Vinita Gottipati, MD

CONTACT

[email protected]

518-262-5013

Sponsors and collaborators

Lead sponsor

Albany Medical College

Other

Registry information

Acronym: BLISS

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
May 6, 2026
Registry last updated
May 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.